Company Overview and News

 
J&J Baby Powder litigation takes new focus with asbestos claims

2018-04-16 channelnewsasia
NEW YORK: A US$117 million verdict against Johnson & Johnson and a supplier in favor of a man who said his asbestos-related cancer was caused by long-term use of J&J's Baby Powder could open a new front for thousands of cases claiming the widely-used product caused cancer, legal experts and plaintiffs lawyers said.
Upvote Downvote

 
J&J Baby Powder litigation takes new focus with asbestos claims

2018-04-16 reuters
NEW YORK (Reuters) - A $117 million verdict against Johnson & Johnson (JNJ.N) and a supplier in favor of a man who said his asbestos-related cancer was caused by long-term use of J&J’s Baby Powder could open a new front for thousands of cases claiming the widely-used product caused cancer, legal experts and plaintiffs lawyers said.
Upvote Downvote

 
J&J Baby Powder litigation takes new focus with asbestos claims - Channel NewsAsia

2018-04-16 channelnewsasia
A US$117 million verdict against Johnson & Johnson and a supplier in favor of a man who said his asbestos-related cancer was caused by long-term use of J&J's Baby Powder could open a new front for thousands of cases claiming the widely-used product caused cancer, legal experts and plaintiffs lawyers said.
Upvote Downvote

 
J&J, Imerys unit must pay US$117 million in asbestos cancer case

2018-04-12 channelnewsasia
NEW YORK: Johnson & Johnson and Imerys Talc America, a unit of Imerys SA, must pay US$117 million in damages in a case involving a man who said he developed cancer due to his exposure to asbestos in talc-based products, a New Jersey state court jury said on Wednesday.
Upvote Downvote

 
Asbestos in Talc Products Verdict Means J&J, Imerys Owe Millions - Bloomberg

2018-04-11 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
J&J, Imerys unit must pay US$117 million in N.J. asbestos cancer case

2018-04-11 channelnewsasia
Johnson & Johnson and an Imerys SA unit must pay an additional US$80 million in punitive damages in a lawsuit claiming a man developed cancer due to his exposure to asbestos in talc-based products, a New Jersey state court jury said on Wednesday.
Upvote Downvote

 
Johnson & Johnson, Imerys must pay US$80 million punitive damages in case linking cancer to asbestos in talc - Channel NewsAsia

2018-04-11 channelnewsasia
Johnson & Johnson and an Imerys SA unit must pay an additional US$80 million in punitive damages in a lawsuit claiming a man developed cancer due to his exposure to asbestos in talc-based products, a New Jersey state court jury said on Wednesday.
Upvote Downvote

 
J&J, Imerys must pay $80 mln punitive damages in case linking cancer to asbestos in talc

2018-04-11 reuters
NEW YORK (Reuters) - Johnson & Johnson and an Imerys SA unit must pay an additional $80 million in punitive damages in a lawsuit claiming a man developed cancer due to his exposure to asbestos in talc-based products, a New Jersey state court jury said on Wednesday.
Upvote Downvote

 
NJ Man Wins $37 Million in J&J Baby Powder Case

2018-04-06 investorplace
Johnson & Johnson (NYSE:JNJ) — aka J&J — is shelling out $37 million to a man over one of its products containing an ingredient that resulted in one of its customers getting cancer.
Upvote Downvote

 
J&J, Imerys must pay US$37 million in case over talc cancer risks: jury - Channel NewsAsia

2018-04-05 channelnewsasia
Johnson & Johnson and Imerys SA must pay at least US$37 million in a lawsuit claiming a man developed cancer due to his exposure to asbestos in talc-based products including Johnson's Baby Powder, a New Jersey state court jury said on Thursday.
Upvote Downvote

 
J&J Ordered to Pay $37 Million Over Banker's Talc Cancer Claims - Bloomberg

2018-04-05 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
J&J Jury Set to Weigh Banker's Claims Baby Powder Caused Cancer - Bloomberg

2018-04-04 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Global Pulp and Paper Chemicals Industry

2017-09-21 prnewswire
This report analyzes the worldwide markets for Pulp and Paper Chemicals in US$ Thousand by the following Product Groups: Pulping & Deinking Chemicals, Bleaching Chemicals, Starches, Internal Sizing Agents, Surface Sizing Agents, Paper Coating Chemicals, Retention & Drainage Aids, and Others. Read the full report: https://www.reportlinker.com/p05112914 The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
Upvote Downvote

 
Notice of Conditional Redemption

2017-07-07 londonstockexchange
€200,000,000 5.75% Senior Secured Fixed Rate Notes due 2021 and €175,000,000 Senior Secured Floating Rate Notes due 2021
Upvote Downvote

 
Graniz Mondal Inc. Announces Proposed Transaction With Group NanoXplore Inc.

2017-06-08 marketwired
Graniz Mondal Inc. (TSX VENTURE:GRA.H) ("Graniz" or the "Corporation") announced today that it has entered into a letter of intent dated June 6, 2017 with Group NanoXplore Inc. ("NanoXplore" or "GNI"), a corporation incorporated under the laws of Quebec, pursuant to which Graniz and NanoXplore intend to complete a business combination (the "Proposed Transaction"), in accordance with Policy 5.2 of TSX Venture Exchange (the "Exchange").
Upvote Downvote

Related Articles

LPCN: Lipocine Inc Analysis and Research Report

8h - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...